Short Bowel Syndrome Market

Short bowel syndrome (SBS) is a metabolic disorder occurs when the portion of the small intestine is not functioning or removed through surgery due to digestive illness. SBS is caused by lack of function of the small intestine. This results in malabsorption, diarrhea, steatorrhea, fluid and electrolyte disturbances, and malnutrition.

Short Bowel Syndrome Market contains market size and forecasts of Short Bowel Syndrome(SBS) in Global, including the following market information:

• Global Short Bowel Syndrome(SBS) Market Revenue, 2017-2022, 2023-2028, ($ millions)
• Global top five companies in 2021 (%)

The global Short Bowel Syndrome(SBS) market was valued at 895.2 million in 2021 and is projected to reach US$ 3837 million by 2028, at a CAGR of 23.1% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Oral Route Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Short Bowel Syndrome(SBS) include Merck, Takeda, Emmaus Medical, Ardelyx, Naia Pharmaceuticals, Nutrinia, OxThera, Sancilio Pharmaceuticals and Zealand Pharma. etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Short Bowel Syndrome(SBS) companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Short Bowel Syndrome(SBS) Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Short Bowel Syndrome(SBS) Market Segment Percentages, by Type, 2021 (%)

• Oral Route
• Parental Route

Global Short Bowel Syndrome(SBS) Market, by Sale Channel, 2017-2022, 2023-2028 ($ millions)

Global Short Bowel Syndrome(SBS) Market Segment Percentages, by Sale Channel, 2021 (%)

• Hospitals
• Clinics
• Retail Pharmacies

Global Short Bowel Syndrome(SBS) Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Short Bowel Syndrome(SBS) Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

• Key companies Short Bowel Syndrome(SBS) revenues in global market, 2017-2022 (estimated), ($ millions)
• Key companies Short Bowel Syndrome(SBS) revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Merck
• Takeda
• Emmaus Medical
• Ardelyx
• Naia Pharmaceuticals
• Nutrinia
• OxThera
• Sancilio Pharmaceuticals
• Zealand Pharma